GLP‑1 therapy after sleeve was associated with better 10-year weight outcomes

What happened

A Yale-affiliated research team led by Matthew Hornick published a study in the International Journal of Obesity examining whether adjuvant semaglutide or tirzepatide use was associated with greater long-term weight loss after sleeve gastrectomy.

In the 111-patient cohort, use of semaglutide or tirzepatide at the most recent visit was associated with 25.7% average total weight loss roughly 10.7 years after surgery, compared with 14.1% among patients not taking those medicines about 10.6 years after surgery. The observed gap was statistically significant (p < 0.001), but treatment was not randomized.

The result adds to observational evidence on anti-obesity medication after sleeve gastrectomy. It does not establish the best sequence of treatments or prove that medication caused the difference.

The investigators retrospectively reviewed records of all adult patients at their single institution who underwent sleeve gastrectomy before age 45 between January 2013 and December 2014. To be included, patients needed BMI data available at least 9.5 years after surgery; anyone converted to gastric bypass along the way was excluded. That left 111 patients.

At the most recent visit, 44 were taking adjuvant anti-obesity medication (29 semaglutide, 15 tirzepatide) for at least one year, and 67 were not. On average, patients started the medication 7.6 years after surgery and had been on it about 3.0 years at the most recent visit. Crucially, the two groups had similar weight-loss trajectories before the medications started, which weakens (though it cannot eliminate) the alternative explanation that the medication group was simply made up of people who did better all along.

The study was approved by the Yale University Institutional Review Board, and the authors declared no competing interests.

What it means

This cohort adds evidence that post-sleeve anti-obesity medication use can be associated with greater long-term weight loss. Its main strength is the decade-long follow-up and similar pre-medication trajectories; its main limit is that treatment was not assigned.

The study supports further research on combined surgical and medical care. It does not establish that the approaches work best in a particular sequence or that every patient with weight regain should use semaglutide or tirzepatide.

What it does not mean

It does not prove the medication caused the difference. This is a retrospective chart review, not a randomized trial. People who ended up on semaglutide or tirzepatide may differ from those who did not in insurance coverage, access to prescribers, motivation, severity of regain, or other health factors, any of which could bias the comparison despite the similar baseline trajectories.

It does not say every post-sleeve patient needs a GLP-1. Many maintain their loss for a decade without medication; the 67 non-users in this study are that story.

It does not compare surgery plus medication against medication alone, so it cannot tell someone without surgery whether they should skip the operating room. And the population is specific: younger adults (all under 45 at surgery), one institution, operations done in 2013-2014, conversions excluded. Whether results extend to older patients, to bypass recipients, or to today's technique mix is untested here.

One structural limitation worth naming honestly: the full methods and discussion sections sit behind the journal's paywall, so this desk verified the abstract, registration details, ethics declarations, and multiple independent secondary reports rather than the complete paper. Sample size (111, with 44 in the medication group) limits precision, and subgroup splits like semaglutide versus tirzepatide are too small to compare drugs against each other.